In 2026, Firalis strategically sold its majority stake in Firalis Molecular Precision to Janvier Group Biosciences. Firalis remains a minority shareholder in the business.
Today, Firalis Molecular Precision operates as Precursion, continuing its mission to accelerate precision medicine through advanced genomics, proteomics, bioinformatics, biomarker research and biobanking.
For all CRO, bioanalytical and multi-omics activities, please visit the Precursion website.
